Research Article
[Retracted] Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer
Table 3
Association of CYFRA21-1 with clinical data of NSCLC patients (n, %).
| | Index | Relative expression of CYFRA21-1 | value | | High expression (n = 30) | Low expression (n = 30) |
| | Age | | ≥60 years (n = 33) | 19 | 14 | 0.195 | | <60 years (n = 27) | 11 | 16 | | Gender | | Male (n = 35) | 15 | 21 | 0.114 | | Female (n = 24) | 15 | 9 | | Tumour size | | ≥3 cm (n = 30) | 12 | 18 | 0.121 | | <3 cm (n = 30) | 18 | 12 | | Clinical staging | | I + II (n = 37) | 14 | 23 | | | III + IV (n = 23) | 16 | 7 | | Lymph node metastasis | | Yes (n = 18) | 12 | 6 | 0.091 | | None (n = 42) | 18 | 24 | | Tumour type | | Squamous cell carcinoma (n = 27) | 18 | 9 | | | Adenocarcinoma (n = 33) | 12 | 21 |
|
|
Note. denotes a notable difference. |